This week, the NIH canceled a round of grant-review meetings, reportedly as part of the transition between presidential administrations.

This move impacts ongoing projects including medical research and clinical trials, with negative consequences for some researchers that may last beyond the initial pause period. As the Trump administration sets a new path for federal grantmaking agencies including the NIH, there are opportunities for needed reforms but also risks of disruption to vital research. 

HxA urges the NIH's interim and incoming leadership to be precise and conservative in its short-term pauses and transparent with the scientific community about upcoming changes. We will continue to monitor the situation.